Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer

Innate and acquired resistance is the principle factor limiting the efficacy of tyrosine kinase inhibitors (TKIs) in lung cancer. We have observed a dramatic upregulation of the cell surface co-receptor neuropilin-2b (NRP2b) in lung cancers clinically treated with TKIs correlating with acquired resistance. We hypothesize that NRP2b plays a functional role in acquired TKI resistance.

Source: The Journal of Thoracic and Cardiovascular Surgery - May 24, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Anastasios Dimou, Cecile Nasarre, Yuri K. Peterson, Rose Pagano, Monika Gooz, Patrick Nasarre, Harry A. Drabkin, Kent E. Armeson, Barry C. Gibney, Robert M. Gemmill, Chadrick E. Denlinger Source Type: research